Potassium-Sparing Diuretics Market Size & Share, by Application (Edema, Hypertension, Heart Failure, Liver Cirrhosis); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3292
  • Published Date: Apr 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Potassium-Sparing Diuretics Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck Sharp & Dohme Corp.
    • Accord Healthcare
    • Amneal Pharmaceuticals LLC
    • Centaur Pharmaceuticals Pvt. Ltd.
    • Validus Pharmaceuticals LLC
    • Teva Pharmaceutical Industries Ltd.
    • CMP Pharma
    • Boehringer Ingelheim GmbH
    • Bayer AG

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • A new FDA approval for Merck & Co., Inc., VERQUVO® (vericiguat) has been announced. heart failure (HF) hospitalization risk reduction with VERQUVO in adults with symptomatic chronic heart failure and a low ejection fraction (45%) after heart failure hospitalization or need for intravenous (IV) diuretics in adults.

  • In a joint announcement today, Boehringer Ingelheim GmbH and Eli Lilly and Company announced that Jadix® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration for the reduction of cardiovascular death and hospitalization associated with heart failure in adults with heart failure with reduced ejection fractions (HFrEF).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3292
  • Published Date: Apr 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of chronic diseases, such as hypertension and kidney diseases, and the increasing demand for better treatments are the major factors driving the market growth.

The market size of potassium-sparing diuretics is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2023-2035.

High cost of potassium-sparing diuretics, coupled with the availability of generic alternatives are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Pfizer Inc., Merck & Co., Inc., Accord Healthcare, Amneal Pharmaceuticals LLC, Centaur Pharmaceuticals Pvt. Ltd., Validus Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., CMP Pharma, Boehringer Ingelheim GmbH, Bayer AG

The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by application, distribution channel and by region.

The hypertension segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying